Evaxion A/S (EVAX) vs INmune Bio (INMB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
INmune Bio (INMB) has outperformed Evaxion A/S (EVAX) over the past year, losing 45.2% versus a loss of 56.6%. Over five years, INMB leads with a -93.8% price change compared with -99.1% for EVAX. INmune Bio is the larger company by market cap ($25.6 million vs $20.8 million), about 1.2 times the size.
Evaxion A/S converts more of its revenue into profit, with a net margin of -102.4% versus -91866.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EVAX | INMB |
|---|---|---|
| Share price | $2.25 | $0.827 |
| Market cap | $20.75M | $25.60M |
| 1-day change | +10.84% | -7.50% |
| YTD return | -52.83% | -46.99% |
| 1-year return | -56.56% | -45.23% |
| 5-year return | -99.07% | -93.80% |
| EPS (TTM) | $-1.00 | $-0.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $7.53M | $50.00K |
| Revenue growth (YoY) | +125.12% | +257.14% |
| Net income (latest FY) | $-7.71M | $-45.93M |
| Operating margin | -122.66% | -94766.00% |
| Net margin | -102.38% | -91866.00% |
| 52-week high | $6.92 | $2.60 |
| 52-week low | $2.03 | $0.8189 |
| Distance from 52-week high | -67.49% | -68.19% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +400.00% | +746.43% |
| Average volume | 85.00K | 338.47K |
| Shares outstanding | 9.22M | 30.96M |
| Employees | 46 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INMB has outperformed EVAX by 11.3 percentage points over the past year.
- Evaxion A/S is more profitable, keeping -102.4 cents of every revenue dollar as net income versus -91866.0 cents for INmune Bio.
- INmune Bio grew revenue faster in its latest fiscal year (+257.14% vs +125.12%).
About Evaxion A/S
EVAX stock →Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 46 employees
About INmune Bio
INMB stock →INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 21 employees
EVAX vs INMB FAQ
Which is bigger, Evaxion A/S or INmune Bio?
INmune Bio (INMB) is larger, with a market capitalization of $25.60M compared with $20.75M for Evaxion A/S (EVAX).
Which stock has performed better over the past year, EVAX or INMB?
INMB returned -45.23% over the past 12 months, compared with -56.56% for EVAX (price return, excluding dividends). Past performance does not predict future results.
Are Evaxion A/S and INmune Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.